Company Encyclopedia
View More
name
Lite Strategy
LITS.US
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc.
1.875 T
LITS.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking0/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-89.74%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-221.06%E
    • Total Assets YoY-70.84%E
    • Net Assets YoY-61.71%E
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio5.96%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lite Strategy Inc. Issues Correction to November 18 SEC Filing

    Lite Strategy Inc. has corrected its November 18 SEC filing, clarifying that CEO Justin J. File was granted options to purchase 180,000 shares, not 635,000 shares as previously reported. The board approved replacement options, pending shareholder approval of a new equity plan.

    Reuters·
    US
    LITS
    0.00%
    Reuters·
    US
    LITS
    0.00%

    Lite Strategy Inc. Director James P. Flynn Reports Acquisition of Common Shares

    James P. Flynn, Director of Lite Strategy Inc., has acquired common shares of the company. This information was published via EDGAR by Lite Strategy Inc. on November 20, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    LITS
    0.00%
    Reuters·
    US
    LITS
    0.00%

    Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing

    Nov 18 (Reuters) - Lite Strategy Inc:* LITE STRATEGY INC - ON NOV 14, BOARD APPROVES JUSTIN J. FILE AS PERMANENT CEO - SEC FILING* LITE STRATEGY INC - JUSTIN J. FILE CONTINUES AS CFO AND SECRETARY - SEC FILING Further company coverage:

    Reuters·
    US
    LITS
    0.00%
    Reuters·
    US
    LITS
    0.00%

    Lite Strategy Reports Improved Earnings and New Focus

    Lite Strategy reported a Q1 net loss of $3.6 million, improved from last year's $8 million loss. The company is shifting focus to include a Litecoin Treasury Strategy, increasing stockholders’ equity to $112.3 million through a $100 million PIPE and warrants. Operating expenses decreased due to reduced R&D costs. Lite Strategy plans to focus on digital asset management and pre-clinical development, confident in funding operations for the next 12 months.

    Tip Ranks·
    US
    LITS
    0.00%
    Tip Ranks·
    US
    LITS
    0.00%

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    Lite Strategy, Inc. reported its first quarter fiscal year 2026 results, highlighting the successful launch of a $100M Litecoin treasury strategy. The company rebranded from MEI Pharma to Lite Strategy, adopting Litecoin as its primary reserve asset. It entered a strategic partnership with GSR and announced a $25M share repurchase program. As of September 30, 2025, Lite Strategy had $12.21M in working capital with no debt, marking its move into active capital market operations.

    The Daily Hodl·
    US
    LITS
    0.00%
    The Daily Hodl·
    US
    LITS
    0.00%